EC Paediatrics

A 10-year-old boy was referred for assessment of growth failure. After normal early growth, he showed progressive decline in height velocity. Endocrine evaluation revealed severe growth hormone (GH) deficiency, and neuroimaging identified a suprasellar cystic lesion compatible with craniopharyngioma. Subtotal resection followed by stereotactic radiotherapy resulted in panhypopituitarism, requiring replacement with desmopressin, levothyroxine, hydrocortisone, and testosterone. Subsequent GH therapy improved final height to 170.6 cm. Treatment adherence was initially poor but improved markedly after switching to an automated injection device. This case highlights the importance of neuroimaging in GH deficiency, careful multidisciplinary follow-up after craniopharyngioma, and the crucial role of adherence-enhancing devices in optimising long-term GH therapy outcomes.

 Keywords: Growth Hormone Therapy; Panhypopituitarism; Craniopharyngioma

1. E Venegas., et al. “Guía práctica del manejo y tratamiento de los craneofaringiomas y otras lesiones paraselares”. Endocrinología y Nutrición 1 (2015): e1-e13.
2. M Güemes Hidalgo., et al. “Secuelas endocrinológicas en niños y adolescentes supervivientes de tumores del sistema nervioso central tras 5 años de seguimiento”. Anales de Pediatría 6 (2014): 357-364.
3. Rodríguez Arnao MD., et al. “Adherence and long-term outcomes of growth hormone therapy with easypodTM in pediatric subjects: Spanish ECOSstudy”. Endocrine Connections9 (2019): 1240-1249.
4. Dahlgren J., et al. “Patient acceptance of a novel electronic auto-injector device to administer recombinant human growth hormone: results from an open-label, user survey of everyday use”. Current Medical Research and Opinion7 (2007): 1649-1655.
5. De Arriba Muñoz A., et al. “Impact of adherence on growth response during the first 2 years of growth hormone treatment”. Endocrine2 (2021): 513-523.
6. Fernandez-Luque L., et al. “Digital health for supporting precision medicine in pediatric endocrine disorders: opportunities for improved patient care”. Frontiers in Pediatrics 9 (2021): 715705.
7. Bozzola M., et al. “Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824children and their parents”. BMC Endocrine Disorders 11 (2011): 4.